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Several cleavage products ofcomplement component C3 interact with cellular
membrane receptors and are associated with important biological activities . The
larger fragment of activated C3 (C3b), which binds covalently to surface mem-
branes or antigen-antibody complexes, is a ligand for complement receptor type
I (CRI),' a glycoprotein of ^-200,000 Mr found on erythrocytes, phagocytes,
lymphocytes and other cells (reviewed in reference 1) . CRI has the unusual
property of serving as a cofactor for the further fragmentation ofbound C3b by
a serum enzyme, C3b-inactivator (I) (2-4) . The serum factor 011-1 (H) can also
serve as a cofactor for the reaction between I and covalently bound C3b, but it
is much less effective than CR I on a molar basis (5) .
The initial cleavage reaction ofC3b releases a peptide of 3,000 M, from its a'
chain (6) . The remaining fragment (iC3b) has greatest binding affinity for
membrane receptor CR3 (7), which is found on phagocytes and natural killer
cells . It has been suggested that CR3 consists of two polypeptides of 185,000
and 95,000 M, (8, 9) . Additional cleavages of iC3b by CRI plus I generate C3c
(140,000 M,), which is released into the fluid phase, and C3dg (41,000 M,) (2-
4, 10) . The bound C3dg fragment can be further cleaved in vitro by plasmin,
elastase, and other proteases, into a fragment called C3d (^35,000 M,) (10) .
Indicator particles bearing C3d can attach to and form rosettes with a subpopu-
lation of B lymphocytes (11, 12) and with monocytes after their cultivation on
glass surfaces (13) . The membrane molecules that mediate this interaction are
operationally defined as CR2. Some studies indicate that, in addition to C3d,
CR2 also binds iC3b and C3dg, but the relative affinities of these multiple ligands
for the receptor have not been measured (7) . The purpose of this paper is to
present evidence that CR2 is a glycoprotein of 140,000 M, called B2 that had
* Supported by grants AI 08499, AI 12069, and CA 25369 from the National Institutes of Health .
' Abbreviations used in this paper:
￿
BSA, bovine serum albumin; C, complement ; CR1, CR2, CR3,
complement receptors for the C3 fragments C3b, C3d, and iC3b ; DNP, dinitrophenyl ; E, sheep
erythrocytes ; EAC, sheep erythrocytes coated with antibody and complement components (subscripts
indicate number of hemolytic sites) ; EBV, Epstein-Barr virus ; H, #IH ; I, C3b inactivator ; NP-40,
Nonidet P-40 ; PBS, phosphate-buffered saline ; pl, isoelectric point ; PMSF, phenylmethylsulfonyl
fluoride; SBTI, soybean trypsin inhibitor ; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis .
J . Exp . MED . © The Rockefeller University Press - 0022-1007/83/10/1021/13 $1 .00
￿
1021
Volume 158 October 1983
￿
1021-10331022
￿
MEMBRANE RECEPTOR FOR C3d
been previously identified by Nadler et al. (14) and Bhan et al . (15) on the surface
of B lymphocytes by means of a monoclonal antibody.
Materials and Methods
Materials. Sephadex, CM-Sephadex, Sepharose CL6B, cyanogen bromide (CNBr)-
activated Sepharose 4B, Thiol-Sepharose, Ficoll-Paque, and low molecular weight markers
were from Pharmacia Fine Chemicals, Piscataway, NJ. DE-52 was from Whatman Ltd.,
Maidstone, Kent, England. TPCK-trypsin and porcine elastase were from Worthington
Biochemical Corp., Freehold, NJ. Soybean trypsin inhibitor (SBTI) was from Sigma
Chemical Co., St. Louis, MO. The porcine elastase inhibitor Ac-Ala-Ala-Pro-Ala-CH 2Cl
was from Enzyme Systems Products, Livermore, CA, and the neutrophyl elastase inhibitor
Suc(OMe)-Ala-Ala-Pro-Val-MCA was from Peninsula Laboratories, Inc., Belmont, CA.
RPMI 1640 medium and antibiotics (Pen-Strep) were from Gibco Laboratories, Grand
Island, NY. Nonidet P-40 (NP-40) was from Particle Data, Inc., Elmhurst, IL. X-omat R-
film XR-5 was from Eastman Kodak, Inc., Rochester, NY. Ampholines were from LKB
Instruments, Inc., Gaithersburg, MD. Iodogen was from Pierce Chemical Co ., Rockford,
IL.
Antibodies, Complement Components, and Fragments.
￿
The monoclonal antibody anti-B2
(14) was purified from ascites by filtration on Sepharose CL6B. The first peak (IgM)
contained the antibody activity. Upon sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) analysis, the only visible contaminant on the Coomassie blue-
stained gels was a2-macroglobulin (<5% of the total protein). A monoclonal antibody
(IgM) antidinitrophenyl (DNP) was used as a control. It was purified to homogeneity from
ascites by affinity chromatography on CNBr-activated Sepharose beads bearing a DNP-
bovine serum albumin conjugate (16). The antibodies were eluted in phosphate-buffered
saline (PBS) containing 0.1 M DNP, filtered through a Sephadex G-25 column, and
dialyzed to remove the free hapten. Four monoclonal antibodies to CR1 were purified to
homogeneity (17). A polyclonal antiserum to mouse Ig was prepared by injecting rabbits
with a mixture of mouse monoclonal antibodies of different isotypes. The IgG fraction of
this antiserum was prepared by chromatography on DE-52, and the F(ab')2 fragments
obtained as described (18). Polyclonal, affinity-purified rabbit antibody to mouse IgM was
isolated from this IgG fraction by filtration through CNBr-activated Sepharose 4B,
coupled to a purified monoclonal antibody of the IgM isotype (anti-DNP), and elution
with 3 M potassium thiocyanate. To remove KSCN, the eluate was filtered through a
Sephadex G-25 column equilibrated in PBS. IgM anti-sheep erythrocytes were from
Cordis Laboratories Inc., Miami, FL, and fluorescein-conjugated goat anti-mouse IgM
was from Coulter Electronics, Inc., Hialeah, FL. Guinea pig Cl (19), human C2, C3, and
C4, plasminogen (20), H (21), and I (22) were prepared according to published procedures.
Human C2 was further purified by chromatography on CM-Sephadex C50 and DE-52
and used in the oxidized form (°"YC2) (23).
Sepharose Beads Coupled with Antibodies or C3 Fragments.
￿
5 mg of each monoclonal
antibody was coupled to 1 ml of CNBr-activated Sepharose 4B according to the manufac-
turer's instructions. Thiol-Sepharose-C3d was prepared as follows: 20 mg of C3 were
incubated at 37 ° C for 5 min with 20 kg of TPCK trypsin in the presence of 1 g of Thiol-
Sepharose beads in 0.1 M Tris buffer, pH 8 .0, containing 0 .1 M NaCI. 1 mM phenyl-
methylsulfonyl fluoride (PMSF) was added to stop the reaction . 3 ml of washed beads
bearing 15 mg of C3b were then incubated twice in succession with 300 tag of porcine
elastase at 37°C for 5 h. The reaction was terminated by the addition of the porcine
elastase inhibitor, Ac-Ala-Ala-Pro-Ala-CH2C1. The products of elastase digestion were
examined by SDS-PAGE under nonreducing conditions. The eluate obtained from the
Thiol-Sepharose-C3d beads by treatment with 0.05 M 1-cysteine in 0 .01 M Tris buffer,
pH 8.0, and the supernatant of elastase digestion, purified by gel filtration on Sephadex
G-150, showed major bands of 35,000 and 140,000 M,, respectively (Fig. 1).
Human Cells.
￿
Tonsil cells were suspended in RPMI 1640 containing 10 mM Hepes,
0.02% NaHCO3 and 1% Pen-Strep, pH 7.4. Most of the contaminating erythrocytes andIIDA, NADLER, AND NUSSENZWEIG
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FIGURE 1 .
￿
SDS-PAGE of C3 fragments. C3 (15 ug ; lane 1), C3c (15 ag ; lane 2), and C3d (18
lAg ; lane 3) were subjected to electrophoresis in a 7.5% polyacrylamide gel under nonreducing
conditions and stained with Coomassie blue .
neutrophils were removed by overlaying the tonsil cells onto Ficoll-Paque and centrifuging
at 400 g for 30 min at room temperature . The mononuclear cells that accumulated at the
interface were collected and washed several times by centrifugation in RPMI medium .
Their viability was >95% as determined by trypan blue exclusion .
Epstein-Barr virus (EBV)-transformed B lymphoblastoid lines (Laz 388, Lazy471, and
Lazy475), Burkitt's lymphoma lines (Daudi, Ramos, and Raji), and chronic myelocytic
leukemia line NALM-1 were kindly provided by Dr . Herbert Lazarus, Dana-Farber
Cancer Institute ; Burkitt's lines Namalva and Wilson were provided by Dr . Ian McGrath,
National Cancer Institute .
Surface Labeling ofLymphocytes and Preparation ofExtracts.
￿
4 x 10' tonsil lymphocytes
or Raji cells were washed three times in PBS, resuspended in 100 ul PBS, and incubated
with 1 mCi of "'I in lodogen-coated tubes for 15 min at O°C . Free iodine was removed
from the cells by centrifugation through fetal calf serum . After additional washings by
centrifugation in PBS, the cells were incubated in 100 Al of 0 .5% NP-40 in PBS containing
1 mM PMSF and 50,ug/ml of the synthetic elastase inhibitor, Suc(OMe)-Ala-Ala-Pro-Val-
MCA . After incubation for 30 min at room temperature, 400 j1 of PBS containing the
same protease inhibitors was added and the mixture was centrifuged to remove insoluble
materials . The supernatant was dialyzed against PBS, further diluted to 1 ml with distilled
water, and incubated with 0 .5 ml of packed Sepharose CL6B for 30 min at room
temperature, to remove materials that adhere nonspecifically to the beads . The superna-
tant contained ^-2 x 1 O' cpm,>95% of which could be precipitated in 10% trichloroacetic
acid .
Amity Chromatography ofMembrane Proteins
Chromatography on Sepharose C3.
￿
This was performed as described (24) . Briefly, the
NP-40 extracts were incubated for 1 h at room temperature with 0.5 ml of Sepharose
C.3 . The beads were kept in suspension by rotation of the tube . Then the beads were
packed in a small column, washed with 40 ml of 0 .065 M borate buffer, pH 8 .0, containing
0.05 M NaCl, 0 .1% NP-40, and eluted with 3 x 300,ul of 0.01 M acetate buffer, pH 4.1,
containing 0.5 M NaCI, 0.1% NP-40, and 1 mM PMSF . The eluates containing radioactive
materials were pooled, supplemented with 0 .2 mg/ml of bovine serum albumin (BSA),
and dialyzed against PBS with 0 .1% NP-40 .
Chromatography on Sepharose-Anti-B2 .
￿
This was performed as described above, except
that the packed beads were washed four times with 2 ml of 0.1 M Tris, pH 8 .0, containing
0.3 M NaCl, 0.1% NP-40, and 1 mg/ml BSA, and that the elution was performed with 3
M KSCN . The eluate was then passed through a small column of Sephadex G25
equilibrated in PBS, 0.1% NP-40, and 0.2 mg/ml BSA to remove KSCN, and then
dialyzed against PBS-0 .1% NP-40 .
Rosette Formation .
￿
Sheep erythrocytes (E) were sensitized with rabbit IgM anti-E (A)
and reacted sequentially with purified complement components C1, C4, and °'YC2 at
concentrations sufficient to give 300 hemolytic sites of each component per erythrocyte .
EAC14' -Y2 were then incubated with various amounts of C3 in order to generate the
EAC14"'Y23b intermediates bearing either 1 .5 or 10 C3 sites . The EAC14°x123b cells1024
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were converted to EAC14-Y23bi by incubation for 1 h at 37°C with purified H and I at
final concentrations of 5 and 1 tcg/ml, respectively. EAC14-Y23bi cells were incubated
with 5 ug/ml of plasmin for 30 min at 37°C to generate EAC14-Y23d, Less than 0.1
hemolytic sites per cell remained on this intermediate. For rosette formation, lymphocytes
(106/ml were mixed with EAC14-Y23d (5 X 107/ml) in RPM1 medium containing 10%
fetal calf serum and 1 mg/ml SBTL The tubes were rotated for 30 min at 37°C. In some
experiments lymphocytes were first incubated with antibody to cell surface components
for 30 min at 37°C before the addition of the erythrocyte intermediates. Rosettes were
counted under the microscope as described (25) .
SDS-PAGE,. This was performed according to Laemmli (26). Human C4, a mouse
monoclonal antibody of the IgG 1 isotype, and BSA were used as molecular weight markers
when the electrophoresis was performed under nonreducing conditions. After electro-
phoresis, the gels were stained with Coomassie blue. Radioautography was carried out at
-70°C using Kodak XR-5 film.
Two-dimensional Electrophoresis.
￿
This was carried out by use of a modified O'Farrell
technique (27). Electrofocusing was performed in the first dimension. A mixture of
ampholines of pH 3-10, 6-8, and 9-11 was used to obtain the desired pH range. After
the first dimension run, one strip of the slab gel was cut into 0 .5-cm segments, and these
were eluted with 2 ml degassed, distilled water overnight at room temperature with
continuous agitation . The eluate was counted in a gamma counter and its pH measured.
Other strips were run in the second dimension (SDS-PAGE), and the slab gels were
subjected to radioautography.
Cell Surface Phenotype Determination by Indirect Immunofuorescence.
￿
1-2 X 106 cells were
treated with 0.1 ml of a 1 :100 dilution of anti-B2 or a 1 :100 dilution of an isotype-
identical nonreactive monoclonal antibody, incubated at 4°C for 30 min, and washed
three times by centrifugation . These cells were then reacted with 0 .1 ml of a 1 :60 dilution
of fluorescein-conjugated goat anti-mouse IgM, incubated at 4°C for 30 min, washed
three times, and analyzed on an Epics V cell sorter (Coulter Electronic Inc .). For each
sample, a quantitative assessment of the number of positive cells was made, i .e., the
number of cells reactive with anti-B2 minus the number of cells reactive with the control
antibody, divided by the 10,000 cells tested .
Results
Isolation front the Lymphocyte Membrane ofMolecules with Binding Affinity for C3 as
well asfor Anti-B2. Extracts from ' 251-labeled membranes of Raji cells and tonsil
lymphocytes were subjected to affinity chromatography on Sepharose C3 and
analyzed by SDS-PAGE and radioautography. Both eluates contained a band of
120,000 11, under nonreducing conditions (Fig. 2) and 140,000 Mr under
reducing conditions (not shown). An additional band of 200,000 Mr was seen
only in the eluate from tonsil lymphocytes. The band of 200,000 Mr was identified
as CR1 since it was specifically removed by treatment of the extracts with
Sepharose beads coupled to monoclonal antibodies to CR1 . It appears therefore
that a Cab-like site, with binding affinity for CR1, was exposed on C3 after its
coupling to Sepharose beads .
When the same labeled membrane extracts were subjected to affinity purifi-
cation on Sepharose-anti-B2, the SDS-PAGE radioautography of the eluates
showed a single band with 120,000 1VIr under nonreducing conditions (Fig. 2)
and 140,000 under reducing conditions.
The radiolabeled molecules of 140,000 Mr eluted from either Sepharose C3
or Sepharose-anti-B2 were further analyzed by two-dimensional gel electropho-
resis. The results shown in Fig. 3 demonstrate that all molecules of 140,000 Mr
isolated from tonsil lymphocytes or from Raji cells have the same isoelectric pointIIDA, NADLER, AND NUSSENZWEIG
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FIGURE 2 .
￿
SDS-PAGE and radioautography of polypeptides isolated from surface-labeled
lymphocyte extracts by affinity chromatography . Tonsil lymphocytes were surface labeled,
solubilized, and the extracts pretreated with Sepharose CL6B as described in Materials and
Methods . The extracts (lane 1) were subjected to affinity chromatography on Sepharose C3 .
The eluate (lane 2) containing the polypeptides of 200,000and 140,000M, was absorbed with
Sepharose-anti-CR1 (lane 3) . The extracts were also incubated with 20,ul of either Sepharose-
anti-B2 or with Sepharose-anti-DNP for 1 h at room temperature with continuous agitation,
in 300 jl of PBS containing 0.1% NP-40 and 0 .2 mg/ml BSA, pH 7.4 . The anti-B2 and anti-
DNP beads were then extensively washed, eluted with SDS-PAGE sample buffer, and the
eluates subjected to electrophoresis in 5-10% gradient gels, under reducing (lanes 6, 7) or
nonreducing conditions (lanes 4, 5) . Lanes 4 and 6 contain the eluates from Sepharose-anti-
B2 and lanes 5 and 7 the control eluates from Sepharose-anti-DNP. The SDS-PAGE of lanes
1-3 wasperformed in 5-10% gradient gels undernonreducing conditions .
(pl) of 8 .2 under denaturing conditions, and give superimposable spots on two-
dimensional gels .
Next, we studied the interaction between the molecule of 140,000 M, and C3
fragments . Extracts from ' 21I-surface-labeled lymphocytes were prepared, ab-
sorbed with Sepharose-anti-CR1 to remove the polypeptide of 200,000Mr , and
subjected to affinity chromatography on Sepharose C3 . Samples of the eluate
were incubated for 1 h at room temperature with 20 A,1 of Sepharose beads
bearing C3c, C3d, anti-B2, or anti-DNP . The beads were washed extensively
and counted in agamma counter . The results, summarized in Table I, show that
the polypeptide of 140,000 M,. has binding affinity for C3d and foranti-B2, since
46% of the counts bound to Thiol-Sepharose-C3d and 34% to Sepharose-anti-
B2 . The binding to Sepharose C3c and to the control beads bearing Sepharose
anti-DNP was not significantly different (15-17%) . As expected, the binding to
Sepharose-anti-B2 was reduced from 34 to 16% in the presence of antibodies to
B2 in the fluid phase. It should be pointed out, however, that the fluid-phase
anti-B2 antibodies had little effect on the interaction between the molecules of
140,000 M,. and Thiol-Sepharose-C3d, suggesting that the epitope reacting with
anti-B2 is not the binding site for C3d. The specificity of interaction between
Thiol-Sepharose-C3d and the 140,000 M, molecules was further demonstrated
by incubating the washed beads with 1 ml of 0.05M cysteine in 0.1 M Tris pH
8.0 . 46% of the counts associated with the beads were released . The eluate was
concentrated and analyzed by SDS-PAGE and radioautography . Only two bands,
C3d (35,000 M,) and carrier BSA, were apparent in the stained gel . The
radioautography showed a single labeled band of 140,000 M, (not shown) .
Correlation Between the Expression ofB2 Antigen and C3d Receptor.
￿
Several cell
lines were analyzed simultaneously, both for expression of C3d receptor as
assessed by rosette formation, and for the presence ofB2 antigen, as determined1026
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FIGURE 3 .
￿
Comparison by two-dimensional electrophoresis of the 140,000Mr molecules with
binding affinity for C3 or for anti-B2 . Extracts of surface-labeled Raji cells and tonsil
lymphocytes were affinity purified either on Sepharose C3 or Sepharose-anti-B2 and subjected
to electrofocusing under reducing conditions in slab gels . After focusing, strips of the gel
containing each preparation were cut into segments and extracted with water . The graph
shows results of the measurement of radioactivity and pH of the eluates obtained from strips
containing Raji cell extracts purified on Sepharose C3 (A) ; Raji cells purified on Sepharose-
anti-B2 (") ; and tonsil lymphocyte extracts purified on Sepharose C3 (O) . The tonsil extracts
had been preabsorbed with Sepharose-anti-CR1 to remove the contaminating CR1 . Separate
strips containing the focused materials were subjected to SDS-PAGE and radioautography .
The radioautographs of the Sepharose C3 and Sepharose-anti-B2 affinity-purified Raji cell
extracts are shown in the top and middle panels, respectively . The results show that the
membrane B2 antigen and the membrane protein with binding affinity for C3 have the same
Mrand pl .
by indirect immunofluorescence . The results shown in Table 11 indicate that the
proportion of cells bearing these two phenotypic markers in the different cell
lines is very similar .
Effect of Anti-B2 o)i Rosette Fortination Between Lymphocytes and EAC14°'~123d .
Anti-B2, but not anti-CR 1, inhibited rosette formation between tonsil lympho-
cytes and EAC14°"Y23d in a dose-dependent fashion (Table 111). Although
relatively high antibody concentrations were used, the inhibition was not com-
plete . The effect, however, appears to be specific, since only anti-CR 1, but not
anti-B2, inhibited rosette formation between the lymphocytes andEACI4"123b.
The results of the treatment of Raji cells with anti-B2 alone were variable .
Sometimes a small but significant inhibition of rosette formation withTABLE I
Binding ofthe 140,000 M,- Polypeptide to Immobilized C3 Fragments
or Anti-B2
S, CNBr-activated Sepharose beads; T, Thiol-Sepharose beads.
Final concentration of 330 wg/ml.
Sepharose C3, Sepharose C3c, and Thiol-Sepharose-C3d had 1 .5 x 10'6
molecules bound per ml of acked beads; Sepharose-anti-B2 and Seph-
arose-anti-DNP had 3 x 10' molecules of IgM bound per ml ofpacked
beads. 40 Al of 50% suspensions of beads pretreated with 5 mM of
diisopropylfluorophosphate were centrifuged in a Beckman microfuge
tube. The Sepharose C3-affinity-purified, anti-CRI-absorbed, 1251-la-
beled tonsil lymphocyte extracts were diluted and added to the packed
beads. The incubation with continuous agitation was performed at room
temperature in 300 pI of phosphate buffer containing 0.07 M NaCl,
0.1% NP-40, 1 mg/ml SBTI, 100 rig/ml of the elastase inhibitor, Ac-
Ala-Ala-Pro-Ala-CH2CI, and 0.2 mg/ml of BSA at pH 7.4.
TABLE II
Correlation Between the Expression ofB2 Antigen and Rosette Formation with
EAC14°'='23d
IIDA, NADLER, AND NUSSENZWEIG
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EAC14°"Y23d was detected. More frequently, rosette formation was enhanced,
and the aggregation of erythrocytes onto one pole of the lymphocyte (capping)
was observed. When, however, anti-B2-treated Raji cells were incubated with
F(ab')2 fragments of rabbit IgG or anti-mouse IgM to cross-link the monoclonal
Cell lines
Origin of
cell lines B2 antigen*
Rosette
formation with
EAC 14-'y23d,o
Raji Burkitt lymphoma 78 86
Daudi Burkitt lymphoma 50 59
Laz 388 EBV-transformed 85 77
Laz 471 EBV-transformed 15 20
Laz 475 EBV-transformed 0 1
Namalwa Burkitt lymphoma 7 10
Ramos Burkitt lymphoma 5 0
Wilson Burkitt lymphoma 0 0
Nalm 1 Chronic myelocytic 0 0
leukemia
Beads*
Antibody in
the fluid
phase*
140,000
Input
M, protein
Bound4
cpm cpm (%)
S-anti-B2 None 4,000 1,371 (34.3)
S-anti-B2 Anti-B2 3,900 619 (15.8)
S-anti-DNP None 4,100 639 (15.5)
S-C3 None 3,000 1,005 (33.5)
S-C3c None 3,000 510 (17 .0)
T-C3d None 3,600 1,658 (46.0)
T-C3d Anti-B2 3,500 1,387 (39.6)
T None 3,700 294 (7.9)1028
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TABLE III
Inhibition by Monoclonal Anti-B2 Antibody of Rosette Formation
Between Tonsil Lymphocytes and EAC14°x''23d
Concentra-
TABLE IV
Inhibition of Rosette Formation Between Raji Cells and EAC14°x''23d
by Incubation ofLymphocytes with Monoclonal Antibodies to B2
Followed by a Second Antibody to Mouse Ig
antibodies and, presumably, B2, rosette formation with EAC14°"Y23d was totally
abolished (Table IV). The degree of inhibition was dependent on the dose of
anti-B2. For example, treatment of lymphocytes with 0.5 or 0.05 Ag/ml ofanti-
B2 followed by anti-mouse IgM completely inhibited the binding of
EAC14°"Y23d, but at concentrations of 0.005 ug/ml, anti-B2 was ineffective.
Lymphocytes incubated in 50 ttg/ml ofa nonrelevant monoclonal antibody (IgM
anti-DNP), followed by incubation in 0.5 1tg/ml anti-mouse IgM, were not
impaired in their ability to bind EAC14°"Y23d.
Discussion
The possible identity between the B2 antigen and CR2 was initially suspected
because both markers are associated only with B cells, and because they are
Treatment of
lymphocytes
tion of mon-
oclonal
antibody
Wg/nd
Indicator cells
Rosette forma-
tion
%
Medium - EAC14oxY23d,, 51 .0
Anti-B2 30 14.0
Anti-B2 10 18.9
Anti-B2 3 25.0
Anti-CR1 25 58.6
Medium - EAC14°"Y23b,.5 51 .3
Anti-132 30 47.7
Anti-CRI 5 1 .6
Raji
First
Monoclonal
anti-B2
cells incubated
step
Monoclonal
anti-DNP
with:
Second step
Rabbit anti-
mouse IgM
Rosette formation
with
EAC14°"Y23d1.5
Ag/nil %
0.5 - 0.5 0
0.5 - - 21 .2
0.05 - 0.5 2 .5
0.05 - - 21 .3
0.005 - 0 .5 21 .5
- 5 0 .5 28 .0
- 5 - 29 .0
- - 0.5 22 .5
- - - 23 .4IIDA, NADLER, AND NUSSENZWEIG
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similarly distributed among established cell lines (Table 11) and B cell malignan-
cies (28, 29). Indeed, B2 and CR2 are expressed in most chronic B lymphocytic
leukemias and poorly differentiated lymphomas but not in large cell lymphomas
and myelomas, which correspond phenotypically to transformed B lymphoblasts
and plasma cells (30).
Our working hypothesis was confirmed by isolatinga Cad-binding polypeptide
from the membrane of Raji cells and tonsil lymphocytes, and showing that it not
only had the same M, and pI as B2 but also that it was recognized by the
monoclonal antibody to B2 (Fig. 3, Table I). Since it could be argued that other
membrane molecules with binding affinity for Cad were involved in the previ-
ously described phenomenon of rosette formation between B lymphocytes and
C3d-bearing particles, we studied the effect of the treatment of lymphocytes
with anti-B2 on their subsequent interaction with EAC14°"Y23d. As shown in
Table III, when tonsil lymphocytes were treated with the monoclonal antibody,
rosette formation was inhibited. In the case of Raji cells, strong inhibition was
observed only when the lymphocytes were furthertreated with a second antibody
directed against mouse Ig (Table IV).
These observations demonstrate that CR2 is the B2 antigen and suggest also
that the inhibitory effect of the monoclonal antibody on rosette formation is
probably the result of the cross-linking of CR2 on the lymphocyte membrane,
rather than of a direct competition with the ligand for the receptor-binding site.
Indeed, the epitope recognized by anti-B2 and the binding site for CM on the
140,000 Mr polypeptide must be topographically distinct, since the interaction
between purified B2 and Thiol-Sepharose-C3d is not prevented by the mono-
clonal antibody (Table I).
Other investigators have used methods similar to those described here to
identify membrane molecules with binding affinity for immobilized and dena-
tured C3 or C3 fragments in lymphoid cells and macrophages. Barel et al. (31)
isolated a glycoprotein of 140,000 A from Raji cells and characterized it as a
C3b receptor. Cole et al. (32) isolated molecules of 140,000 and 63,000 M, from
the membrane of human mononuclear cells and suggested that the smaller
polypeptide was derived from the larger one. Lambris et al . (33) purified a C3d-
binding glycoprotein (73,000 Mr) from the supernatant of cultures of Raji cells
and identified it as CR2, but other CM-binding polypeptides with higher A
were observed during the intermediate steps of purification. In light of the
present studies, we speculate that the protein of 140,000 A described by the
above-mentioned investigators may be identical to B2, and that the smaller
polypeptides represent degradation products. Further studies are necessary to
clarify this point.
Previous studies of the distribution of B2 antigen provide significant insight
into the cellular expression of the Cad receptor. Within the hematopoietic
system, the B2 antigen is found in the majority of B cells from peripheral blood
and lymphoid organs but not on mature or progenitor cells of myeloid, erythroid,
or T lymphoid lineage (14, 34).
Several lines of evidence suggest that the expression of B2 is limited to discrete
stages of B cell differentiation. B2 is detected simultaneously with or after the
appearance of IgM in the cytoplasm of pre-B cells, and is lost from the cell1030
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surface when B cells develop lymphoblastoid morphology and lose cell surface
IgD (30). B2 is more strongly expressed on cells from lymphoid organs than
from peripheral blood (14), but after stimulation with pokeweed mitogen, the
amount of B2 on peripheral blood B cells increases. After 4-5 d in culture, when
stimulated B cells develop presecretory cytoplasmic IgM and lose surface IgD,
the B2 antigen disappears (34). In lymphoid organs, B2 is weakly expressed on
cells of primary follicles or in the mantle zone of secondary follicles, but very
strongly in germinal centers. Interestingly, in the latter location, B2 antigen also
appears to be present between cells, suggesting that it may be shed (15).
The function of CR2 is not known. Many reports in the literature (reviewed
in reference 35) suggest that cleavage products of C3 play a role in immuno-
regulation, but it has been very difficult to clarify the nature of the C3 fragments
and C3 receptors involved. Particularly intriguing are the observations that the
retention of antigen in lymphoid follicles, as well as the development of B
memory cells and germinal centers, are antibody- and C3-dependent processes
(36-38). These studies have been interpreted as meaning that the generation of
B memory cells is triggered by antigen-antibody-C3 fragmentstrapped in follicles
by complement receptors (39). Since the fragments that remain associated with
immune complexes after the cleavage of bound C3b by CR1 + I are most likely
C3dg (40), CR2 could be involved in this process.
Summary
The B2 antigen characterized by means of a monoclonal antibody (14) is a
140,000 Mr protein expressed only in certain stages of the differentiation of
lymphocytes of the B lineage. Here we examine the relationship between B2 and
the membrane complement receptor type 2 (CR2) for the complement fragment
C3d (11, 12), which is also associated only with B cells. Both phenotypic markers
are distributed in a similar manner among B cell malignancies and, as shown
here, among established cell lines.
A polypeptide with binding affinity for C3d was isolated from the membrane
of B2-positive cells, i.e., tonsil lymphocytes and Raji cells. We found that this
C3d-binding protein not only had the same M, and isoelectric point (pl) as the
B2 antigen, but that it was recognized by the monoclonal antibody to B2 .
However, anti-B2 does not mask the ligand-binding site of CR2 since it does not
prevent the interaction of the purified 140,000Apolypeptide with immobilized
C3d.
Rosette formation between tonsil lymphocytes and erythrocyte intermediates
bearing C3d was specifically inhibited by anti-B2. In the case of Raji cells, rosette
formation was strongly inhibited only when the lymphocytes were sequentially
treated with anti-B2 and with a polyclonal antibody against mouse Ig.
In short, B2 and CR2 have a similar distribution among normal and malignant
cells, have the same M, and pl under denaturing conditions, and react with a
single monoclonal antibody. We conclude that B2 is identical to CR2.
We thank Richard Melton for technical assistance andJoanne Joseph and Roger Rose for
manuscript preparation.
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